Beam Therapeutics (BEAM) News Today $16.99 +0.32 (+1.92%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$17.16 +0.17 (+0.99%) As of 06/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BEAM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Recommendation of "Buy" by AnalystsShares of Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) have been given an average recommendation of "Buy" by the fifteen analysts that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation, eleven have issued a buy recommenJune 18 at 4:12 AM | marketbeat.comGAMMA Investing LLC Raises Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)GAMMA Investing LLC raised its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 549.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 37,185 shares of the company's stock after purchasJune 18 at 3:13 AM | marketbeat.comEli Lilly’s $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know.June 17 at 1:39 PM | msn.comBeam Therapeutics (NASDAQ:BEAM) Shares Gap Up - Should You Buy?Beam Therapeutics (NASDAQ:BEAM) Shares Gap Up - Time to Buy?June 17 at 12:16 PM | marketbeat.comRhumbline Advisers Acquires 14,971 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Rhumbline Advisers raised its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 11.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 141,204 shares of the company's stock afterJune 16 at 3:22 AM | marketbeat.comBeam reports positive results from sickle cell disease treatmentJune 13, 2025 | msn.comBeam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 CongressJune 13, 2025 | globenewswire.comCantor Fitzgerald Forecasts BEAM FY2026 EarningsJune 13, 2025 | americanbankingnews.comCathie Wood’s ARK ETFs adjust holdings, buying GitLab and Beam Therapeutics stockJune 12, 2025 | investing.comEquities Analysts Set Expectations for BEAM FY2026 EarningsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Beam Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company will post earnings of ($2.92) per shareJune 11, 2025 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Shares Gap Up - What's Next?Beam Therapeutics (NASDAQ:BEAM) Shares Gap Up - What's Next?June 6, 2025 | marketbeat.comBeam gets FDA orphan drug status for sickle cell disease treatmentJune 3, 2025 | msn.comBeam Therapeutics Gets FDA Orphan Drug Designation for Sickle-Cell Disease TreatmentJune 3, 2025 | marketwatch.comBeam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell DiseaseJune 3, 2025 | globenewswire.comTwo Sigma Investments LP Increases Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Two Sigma Investments LP raised its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 75.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 117,088 shares of the company's stock after acquiring an additioJune 1, 2025 | marketbeat.comBank of America Corp DE Has $3.40 Million Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)Bank of America Corp DE lessened its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 74.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 136,933 shares of the company's stock after selling 403,054 shares during the qJune 1, 2025 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Trading Down 2.7% - Time to Sell?Beam Therapeutics (NASDAQ:BEAM) Trading Down 2.7% - Time to Sell?May 30, 2025 | marketbeat.comFDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)’ AATD Gene TherapyMay 30, 2025 | msn.comBeam Therapeutics Says FDA Grants Orphan Drug Designation to Lung, Liver TreatmentMay 29, 2025 | marketwatch.comSA analyst upgrades: NVDA, DJT, VKTX, BRK.A, BEAMMay 29, 2025 | msn.comBeam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)May 29, 2025 | uk.finance.yahoo.comBeam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)May 29, 2025 | globenewswire.comBeam Therapeutics: A Cautious Hold On A Base Editing PioneerMay 29, 2025 | seekingalpha.comCandel Shares Rise After FDA Regenerative Medicine Advanced Therapy DesignationMay 29, 2025 | marketwatch.comPolar Asset Management Partners Inc. Has $5.17 Million Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)Polar Asset Management Partners Inc. lifted its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 901.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 208,255 shares of the companyMay 28, 2025 | marketbeat.comSquarepoint Ops LLC Invests $3.85 Million in Beam Therapeutics Inc. (NASDAQ:BEAM)Squarepoint Ops LLC bought a new position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 155,278 shares of the company's stock, valued at approximately $3,851,000. Squarepoint OpMay 28, 2025 | marketbeat.comVoloridge Investment Management LLC Has $10.25 Million Stake in Beam Therapeutics Inc. (NASDAQ:BEAM)Voloridge Investment Management LLC reduced its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 10.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 413,409 shares of the company's stock after selling 50,253May 27, 2025 | marketbeat.comWoodline Partners LP Takes Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Woodline Partners LP purchased a new position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 282,120 shares of the company's stock, valuMay 26, 2025 | marketbeat.comDeutsche Bank AG Has $1.67 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Deutsche Bank AG grew its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 54.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 67,508 shares of the company's stock after purchasing an additional 23,871 shares duringMay 26, 2025 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of "Buy" from AnalystsShares of Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) have been assigned an average rating of "Buy" from the fifteen analysts that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, eleven have aMay 26, 2025 | marketbeat.comGoogle Beam Futuristic AI-Powered 3D Video Chats Are Coming This YearMay 23, 2025 | msn.comTwinbeech Capital LP Purchases 69,456 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Twinbeech Capital LP boosted its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 119.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,664 shares of the company's stock after buyinMay 23, 2025 | marketbeat.comRafferty Asset Management LLC Has $2.76 Million Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Rafferty Asset Management LLC lowered its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 40.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 111,100 shares of the company's stock after selliMay 22, 2025 | marketbeat.comPoint72 Asset Management L.P. Buys Shares of 193,356 Beam Therapeutics Inc. (NASDAQ:BEAM)Point72 Asset Management L.P. bought a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 193,356 shares of the company's stock, valued aMay 22, 2025 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Tang Capital Management LLCTang Capital Management LLC lowered its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 70.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,000 shares of the company's stock after selling 120,00May 20, 2025 | marketbeat.comRaiffeisen Bank International AG Invests $1.26 Million in Beam Therapeutics Inc. (NASDAQ:BEAM)Raiffeisen Bank International AG purchased a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 50,000 shares of the company's stock, valMay 19, 2025 | marketbeat.comPolar Asset Management Partners Inc. Acquires 187,455 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Polar Asset Management Partners Inc. increased its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 901.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 208,255 shares of the company's stock after acquiMay 18, 2025 | marketbeat.comHudson Bay Capital Management LP Sells 15,000 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Hudson Bay Capital Management LP cut its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 13.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 100,000 shares of the company's stock after selling 15May 16, 2025 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Northern Trust CorpNorthern Trust Corp boosted its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 7.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 740,506 shares of the company's stock after acquiring an additional 49,415 shares during the periMay 16, 2025 | marketbeat.comAlgert Global LLC Has $233,000 Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Algert Global LLC reduced its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 78.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,378 shares of the company's stock after sellMay 15, 2025 | marketbeat.comBeam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 CongressMay 14, 2025 | globenewswire.comBeam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare ConferenceMay 13, 2025 | globenewswire.comHC Wainwright Issues Positive Forecast for BEAM EarningsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Research analysts at HC Wainwright upped their Q2 2025 EPS estimates for Beam Therapeutics in a research note issued to investors on Wednesday, May 7th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($May 13, 2025 | marketbeat.comBeam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)May 12, 2025 | globenewswire.comLeerink Partnrs Issues Optimistic Forecast for BEAM EarningsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Research analysts at Leerink Partnrs increased their Q2 2025 earnings per share (EPS) estimates for Beam Therapeutics in a note issued to investors on Tuesday, May 6th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will pMay 11, 2025 | marketbeat.comQ2 EPS Forecast for Beam Therapeutics Reduced by AnalystBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - William Blair cut their Q2 2025 earnings per share estimates for shares of Beam Therapeutics in a research note issued to investors on Tuesday, May 6th. William Blair analyst S. Corwin now expects that the company will post earnings of ($1.01)May 11, 2025 | marketbeat.comFarallon Capital Management LLC Purchases 31,000 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Farallon Capital Management LLC raised its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 0.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,239,123 shares of the company's stock after acquiring an aMay 11, 2025 | marketbeat.comCrestline Management LP Increases Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Crestline Management LP grew its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 261.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,969 shares of the company's stMay 11, 2025 | marketbeat.comTudor Investment Corp ET AL Sells 16,242 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Tudor Investment Corp ET AL trimmed its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 49.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,575 sharesMay 11, 2025 | marketbeat.comQ2 Earnings Estimate for Beam Therapeutics Issued By WedbushBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Research analysts at Wedbush cut their Q2 2025 earnings estimates for Beam Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. Wedbush analyst D. Nierengarten now anticipates that the company will post earningMay 10, 2025 | marketbeat.com Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address BEAM Media Mentions By Week BEAM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BEAM News Sentiment▼0.870.64▲Average Medical News Sentiment BEAM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BEAM Articles This Week▼97▲BEAM Articles Average Week Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LEGN News GRFS News TGTX News TLX News NUVL News LNTH News AXSM News ADMA News ZLAB News AKRO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BEAM) was last updated on 6/19/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BEAM Stock Free BEAM Stock Alerts